annb0t
Top 20
The European Medicines Agency (EMA)Â has accepted Travere Therapeutics Inc (NASDAQ: TVTX) and CSL Vifor's (OTC: CSLLY) conditional marketing application for sparsentan for IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD). A review decision on a potential approval is expected in the second half of 2023. The EMA filing is supported by positive topline interim results from the ongoing Phase 3 PROTECT Study. Related Content:FDA Says Travere's Sp...
>>> Read more: Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder
>>> Read more: Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder
